HALO
Strong BuyPremium GrowerAI neutralHalozyme Therapeutics, Inc. · Healthcare · United States · $14.3B cap · $328.9M/day traded
$125.63 +0.9% · close 23 Oct · scored 24 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on HALO (Jun 2026), freeReport expected 2 Nov: the next-year EPS estimate has risen 7.7% over the last 14 weeks.
As of 24 Oct 2026, MoatMap's StockRank for Halozyme Therapeutics, Inc. (HALO) is 94/100, ranked against 24,000+ stocks in 35 markets (Quality 77, Value 33, Momentum 91, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Halozyme earns high-margin royalties from its ENHANZE drug-delivery technology, which lets partners such as Roche, J&J and Bristol Myers convert intravenous drugs to subcutaneous injections. This asset-light model produces high returns on capital. The company recently raised full-year guidance, has an active buyback and is broadening into other drug-delivery platforms. It just priced an upsized $1.3 billion convertible note offering due 2033, adding leverage and potential dilution. The main uncertainty is how durable ENHANZE royalties are as key patents approach expiry later this decade.
ABOUT HALOZYME THERAPEUTICS, INC.
Read
Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary ENHANZE® drug delivery technology, utilizing recombinant human hyaluronidase enzyme (rHuPH20). This innovative platform facilitates subcutaneous administration of biologics, thereby improving patient convenience and reducing healthcare costs. Halozyme operates primarily through a high-margin licensing model, partnering with major pharmaceutical companies to enhance the delivery of their blockbuster therapeutics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 660.1M | 829.3M | 1.0B | 1.4B | 28.4% | 1.7B | 1.9B | 2.1B | 22.6% |
| EPS | 1.48 | 2.13 | 3.50 | 2.64 | 21.3% | 3.42 | — | — | — |
| Shares | 135.2M | 126.8M | 123.1M | 117.8M | -12.9% | 113.5M | — | — | — |
| Debt | 1.5B | 1.5B | 1.5B | 2.1B | 12.5% | 2.2B | — | — | — |
| Equity | 169.8M | 83.8M | 363.8M | 48.8M | -34.0% | — | — | — | — |
| Op CF | 240.1M | 388.6M | 479.1M | 651.6M | 39.5% | 818.6M | — | — | — |
| Inv CF | -487.0M | -96.9M | -262.7M | -545.8M | — | — | — | — | — |
| Fin CF | 362.4M | -408.0M | -218.9M | -85.2M | — | — | — | — | — |
Above its 200-day average and at its 52-week high.
Calmer than 58% of stocks we rank over the past year (37% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HALO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc.(you) | $14.3B | 94 | Strong Buy |
| EXEL | Exelixis, Inc. | $16.0B | 98 | Strong Buy |
| INCY | Incyte Corporation | $23.5B | 94 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.4B | 73 | Buy |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | 95 | Strong Buy |
| CORT | Corcept Therapeutics Incorporated | $9.3B | 67 | Buy |
| CAI | Caris Life Sciences, Inc. | $9.0B | 68 | Buy |
| KRYS | Krystal Biotech, Inc. | $9.2B | 67 | Buy |
| PTGX | Protagonist Therapeutics, Inc. | $9.0B | 66 | Buy |
| LGND | Ligand Pharmaceuticals Incorporated | $6.1B | 71 | Buy |
Peer medians: ROE -31.5% · P/E 27.3x · Gross margin 62.6%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.